Compare CTMX & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTMX | CPIX |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.2M | 34.1M |
| IPO Year | 2015 | 2009 |
| Metric | CTMX | CPIX |
|---|---|---|
| Price | $4.16 | $2.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 92.6K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.22 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $113,631,000.00 | $41,278,349.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.49 | ★ N/A |
| Revenue Growth | N/A | ★ 12.21 |
| 52 Week Low | $0.40 | $1.85 |
| 52 Week High | $4.62 | $7.25 |
| Indicator | CTMX | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 57.36 | 56.08 |
| Support Level | $3.78 | $2.11 |
| Resistance Level | $4.20 | $2.73 |
| Average True Range (ATR) | 0.24 | 0.23 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 73.88 | 72.60 |
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.